![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: YPEL5 |
Gene summary for YPEL5 |
![]() |
Gene information | Species | Human | Gene symbol | YPEL5 | Gene ID | 51646 |
Gene name | yippee like 5 | |
Gene Alias | CGI-127 | |
Cytomap | 2p23.1 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | P62699 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51646 | YPEL5 | LZE4T | Human | Esophagus | ESCC | 6.55e-14 | 8.59e-01 | 0.0811 |
51646 | YPEL5 | LZE8T | Human | Esophagus | ESCC | 2.45e-04 | 3.31e-01 | 0.067 |
51646 | YPEL5 | LZE20T | Human | Esophagus | ESCC | 1.67e-02 | 3.95e-01 | 0.0662 |
51646 | YPEL5 | LZE24T | Human | Esophagus | ESCC | 1.08e-14 | 9.55e-01 | 0.0596 |
51646 | YPEL5 | LZE6T | Human | Esophagus | ESCC | 5.89e-05 | 7.50e-01 | 0.0845 |
51646 | YPEL5 | P1T-E | Human | Esophagus | ESCC | 1.61e-02 | 8.99e-01 | 0.0875 |
51646 | YPEL5 | P2T-E | Human | Esophagus | ESCC | 1.58e-45 | 1.05e+00 | 0.1177 |
51646 | YPEL5 | P4T-E | Human | Esophagus | ESCC | 7.20e-18 | 7.72e-01 | 0.1323 |
51646 | YPEL5 | P5T-E | Human | Esophagus | ESCC | 9.65e-15 | 4.50e-01 | 0.1327 |
51646 | YPEL5 | P8T-E | Human | Esophagus | ESCC | 5.58e-23 | 7.42e-01 | 0.0889 |
51646 | YPEL5 | P9T-E | Human | Esophagus | ESCC | 7.06e-12 | 5.54e-01 | 0.1131 |
51646 | YPEL5 | P10T-E | Human | Esophagus | ESCC | 3.51e-24 | 6.02e-01 | 0.116 |
51646 | YPEL5 | P11T-E | Human | Esophagus | ESCC | 1.50e-19 | 1.55e+00 | 0.1426 |
51646 | YPEL5 | P12T-E | Human | Esophagus | ESCC | 7.39e-33 | 9.80e-01 | 0.1122 |
51646 | YPEL5 | P15T-E | Human | Esophagus | ESCC | 7.98e-25 | 9.41e-01 | 0.1149 |
51646 | YPEL5 | P16T-E | Human | Esophagus | ESCC | 1.68e-22 | 5.88e-01 | 0.1153 |
51646 | YPEL5 | P20T-E | Human | Esophagus | ESCC | 2.72e-12 | 8.13e-01 | 0.1124 |
51646 | YPEL5 | P21T-E | Human | Esophagus | ESCC | 5.95e-22 | 5.36e-01 | 0.1617 |
51646 | YPEL5 | P22T-E | Human | Esophagus | ESCC | 5.05e-33 | 8.59e-01 | 0.1236 |
51646 | YPEL5 | P23T-E | Human | Esophagus | ESCC | 3.00e-41 | 1.76e+00 | 0.108 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | ![]() |
Oral cavity | LP | ![]() |
Oral cavity | EOLP | ![]() |
Oral cavity | NEOLP | ![]() |
Esophagus | HGIN | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
YPEL5 | SNV | Missense_Mutation | c.5N>A | p.Gly2Asp | p.G2D | P62699 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
YPEL5 | SNV | Missense_Mutation | c.355N>C | p.Asp119His | p.D119H | P62699 | protein_coding | deleterious_low_confidence(0) | benign(0.308) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
YPEL5 | SNV | Missense_Mutation | rs370740580 | c.25A>G | p.Ile9Val | p.I9V | P62699 | protein_coding | tolerated(0.41) | benign(0.003) | TCGA-F4-6703-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
YPEL5 | SNV | Missense_Mutation | c.122N>A | p.Arg41Lys | p.R41K | P62699 | protein_coding | tolerated(0.11) | possibly_damaging(0.622) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
YPEL5 | SNV | Missense_Mutation | c.307C>T | p.Arg103Cys | p.R103C | P62699 | protein_coding | deleterious(0) | benign(0.063) | TCGA-B5-A0JR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
YPEL5 | SNV | Missense_Mutation | c.163G>A | p.Glu55Lys | p.E55K | P62699 | protein_coding | tolerated(0.12) | benign(0.043) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
YPEL5 | SNV | Missense_Mutation | novel | c.175C>T | p.Arg59Trp | p.R59W | P62699 | protein_coding | deleterious(0.04) | probably_damaging(0.997) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
YPEL5 | SNV | Missense_Mutation | novel | c.320N>A | p.Arg107Gln | p.R107Q | P62699 | protein_coding | tolerated(0.65) | benign(0.007) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
YPEL5 | SNV | Missense_Mutation | novel | c.45T>G | p.Phe15Leu | p.F15L | P62699 | protein_coding | tolerated(0.05) | benign(0.038) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
YPEL5 | SNV | Missense_Mutation | novel | c.302T>C | p.Leu101Pro | p.L101P | P62699 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |